Trial profile. Between May 2008 and July 2014, a total of 1945 patients were included in the HD18 trial and received 2 cycles of eBEACOPP followed by PET-2. After a protocol amendment in 2011, the standard arm was modified from 8 to 6 cycles of eBEACOPP (=722 patients). PD, progressive disease.